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Abstract
Background: The epidermal growth factor receptor (EGFR/HER1) and its downstream signaling events
are important for regulating cell growth and behavior in many epithelial tumors types. In breast cancer,
the role of EGFR is complex and appears to vary relative to important clinical features including estrogen
receptor (ER) status. To investigate EGFR-signaling using a genomics approach, several breast basal-like
and luminal epithelial cell lines were examined for sensitivity to EGFR inhibitors. An EGFR-associated gene
expression signature was identified in the basal-like SUM102 cell line and was used to classify a diverse set
of sporadic breast tumors.
Results: In vitro, breast basal-like cell lines were more sensitive to EGFR inhibitors compared to luminal
cell lines. The basal-like tumor derived lines were also the most sensitive to carboplatin, which acted
synergistically with cetuximab. An EGFR-associated signature was developed in vitro, evaluated on 241
primary breast tumors; three distinct clusters of genes were evident in vivo, two of which were predictive
of poor patient outcomes. These EGFR-associated poor prognostic signatures were highly expressed in
almost all basal-like tumors and many of the HER2+/ER- and Luminal B tumors.
Conclusion: These results suggest that breast basal-like cell lines are sensitive to EGFR inhibitors and
carboplatin, and this combination may also be synergistic. In vivo, the EGFR-signatures were of prognostic
value, were associated with tumor subtype, and were uniquely associated with the high expression of
distinct EGFR-RAS-MEK pathway genes.
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Background
The epidermal growth factor receptor (EGFR/HER1) is a
member of the human epidermal growth factor receptor
(HER) family of transmembrane receptor tyrosine kinases
that is linked to growth control, cell adhesion, mobility,
and apoptosis [1]. EGFR is an important regulator of epi-
thelial cell biology, but its function in breast tumors is
complicated by the observation that its function may vary
according to important clinical features like estrogen
receptor (ER) and HER2 status. Microarray studies have
identified several subtypes of breast cancer arising from at
least two different epithelial cell types [2-5]. Two of the
molecular subtypes of breast cancer are partly defined by
the high expression of ER, while a third is partly defined
by the genomic DNA amplification and high expression
of HER2 (i.e. HER2+/ER-, see [5]). The basal-like subtype
has low expression of both ER and HER2, however, most
basal-like tumors highly express EGFR as assessed by both
gene and protein expression [6].
High expression of EGFR has been reported in a variety of
epithelial tumors [7], leading to the development of drugs
directed against this receptor [8,9]. One of these targeting
strategies employs monoclonal antibodies (cetuximab)
that bind the extracellular ligand-binding domain, while
other strategies include small molecule inhibitors (gefit-
inib and erlotinib) that compete with ATP for binding to
the intracellular tyrosine kinase domain [10-12]. In non-
small cell lung cancer and breast cancer cell lines, it has
been shown that some small molecule EGFR inhibitors
increase cell killing when used in combination with
chemotherapeutics [13,14]; therefore, the interactions
between EGFR inhibitors and cytotoxic agents represent a
promising combination for the future treatment of epithe-
lial tumors that are dependent upon EGFR-signaling.
The lack of clinical response in breast cancers treated with
gefitinib in vivo has been partially attributed to activation
of this pathway downstream of EGFR, or ineffective meth-
ods of identifying those tumors that show an EGFR-
dependent signature. EGF independent activation of the
EGFR-pathway via the PI3K/AKT pathway may occur
through either loss of PTEN or mutation/activation of
PI3K, both of which have been linked to gefitinib resist-
ance [15-17]. Others have suggested that the MEK/ERK
pathway may play a more important role in resistance to
EGFR inhibitors [18-20]. Recently, Moyano et al. identi-
fied αB-Crystallin (CRYAB) as a protein that can constitu-
tively activate the MEK/ERK pathway in breast epithelial
cells and caused a cell line to become EGF independent
[21].
In this study, we hypothesized that the breast tumor
"intrinsic" subtypes might vary in dependence upon
EGFR-signaling, which could be reflective of differences in
gene expression patterns. Therefore, we used breast cell
lines to identify an EGFR-pathway associated profile and
examined interactions between EGFR inhibitors and cyto-
toxic chemotherapeutics in vitro. These analyses identified
multiple EGFR-associated profiles in vivo that were of
prognostic significance, showed important links with
tumor subtype, and highlight potential downstream acti-
vators of the EGFR-RAS-MEK pathway.
Results
Cell line models of breast cancer
Breast cancer is a heterogeneous disease arising from at
least two distinct epithelial cell populations, therefore, we
selected cell lines models of basal-like and luminal cells to
begin our investigations of the EGFR-pathway. The MCF-
7 and ZR-75-1 cell lines were derived from breast tumors
of luminal origin and have expression of CK8/18 and ER.
Our previous studies examining cell lines of basal-like ori-
gin used immortalized human mammary epithelial cell
lines (HMECs) [22,23]; however, these lines are derived
from normal rather than tumor tissue. Two ER-negative
and HER2-non-amplified tumor-derived cell lines,
SUM149 and SUM102, have been previously shown to
express EGFR [18,24] and show basal-like expression pro-
files [25]. The SUM102 and SUM149 lines share many
characteristics with the basal-like tumors including
expression of CK5/6, therefore, we included these two
tumor-derived lines as in vitro models of basal-like breast
cancers. By microarray analysis, EGFR gene expression was
low in the luminal cell lines and higher in the basal-like
lines. EGFR protein expression by Western blot analysis
was detectable in the basal-like lines, but not in the lumi-
nal lines (data not shown).
Drug sensitivity assays
To assess EGFR inhibitor sensitivity, the six cell lines
described above were treated for 72 h with a range of
doses of gefitinib or cetuximab and a MTT assay was used
to determine IC50 doses (Table 1). In response to gefit-
inib, the basal-like tumor-derived cell lines (SUM149 and
SUM102) were two- to 100-fold more sensitive than the
luminal lines. The two immortalized HMEC lines were
33- and 50-fold more sensitive to gefitinib than the lumi-
nal lines, suggesting that the basal-like cell lines as a
whole were more sensitive to gefitinib versus the luminal
cell lines. Cetuximab sensitivity was observed in only a
single cell line (SUM102, IC50 = 2 ug/ml), with IC50
doses for MCF-7, ZR-75-1, SUM149, ME16C2, and HME-
CC not achievable even with cetuximab doses as high as
100 ug/ml. These cell lines were also treated with inhibi-
tors that affect targets downstream of EGFR in the path-
way including U1026 (MEK1/2 inhibitor) and LY294002
(PI3K inhibitor). Most of the cell lines had a similar level
of sensitivity to U0126 with the exception that SUM102
was approximately 5-fold more sensitive. IC50 doses forBMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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LY294002 were similar for most lines with the exception
of ME16C and SUM149 cells, which were approximately
5-fold more resistant than the other lines. The SUM102
line was the only cell line that was sensitive to all four
inhibitors and has previously been shown to be EGFR-
dependent [24], and thus, was chosen for further analyses
of the EGFR pathway.
Drug combination analyses
Given the observation that most biologically targeted
drugs like cetuximab typically show low response rates
when tested in vivo alone, we examined the effects of
chemotherapeutics (carboplatin, doxorubicin, 5-fluorou-
racil, and paclitaxel) as single agents across all cell lines
and the combination of cetuximab plus chemotherapeu-
tics in SUM102 cells. Note, we only used the SUM102
cells for the combination studies because they were the
only cell line tested for which an IC50 dose for single
agent cetuximab could be obtained. We also tested the
combined effects of gefitinib, U0126, and LY294002 with
chemotherapeutic agents in SUM102 cells. First, individ-
ual drug sensitivity (IC50 doses) for each chemotherapeu-
tic was determined for all six cell lines (Table 2). The
relative sensitivities varied across the cell lines and did not
appear to correlate with cell type (i.e. basal-like vs. lumi-
nal), with the exception that the two basal-like tumor-
derived cell lines (SUM102 and SUM149) were at least
three-fold more sensitive to carboplatin, and at least two-
fold more resistant to 5-fluorouracil when compared to
their immortalized HMEC counterparts or the luminal
cell lines.
As a starting point for combination experiments, we
treated SUM102 cells for 72 h with cetuximab and a
chemotherapeutic simultaneously. Synergistic interac-
tions were not evident in any combination and all combi-
nations were antagonistic as assessed by the method of
Chou and Talalay in CalcuSyn [26] (Figure 1). We next
analyzed the effect of sequential treatment: cells were
treated for (a) 72 h with cetuximab followed by 72 h with
chemotherapy, (b) 72 h with chemotherapy followed by
72 h with cetuximab, or (c) with cetuximab and chemo-
therapy simultaneously for 144 h. Chemotherapy fol-
lowed by cetuximab was generally more growth
inhibitory than cetuximab followed by chemotherapy
(Figure 1). The one exception was cetuximab with paclit-
axel, where all sequence combinations were antagonistic
(Figure 1). However, this antagonism may result from the
high sensitivity to paclitaxel already observed in the
SUM102 line (Table 2). Carboplatin followed by cetuxi-
mab and the 144 h concurrent treatments were synergistic
even at low doses of both drugs. 5-fluorouracil followed a
similar trend to that of carboplatin, while in the doxoru-
bicin combinations synergy was only evident at doses
higher than the IC50 dose for doxorubicin first, or the 144
h concurrent (Figure 1). Similar results were observed for
combinations with gefitinib and LY294002 (a PI3K inhib-
itor) where chemotherapy followed by each inhibitor,
and the 144 h concurrent treatments, were more effective
Table 2: Estimated IC50 doses of breast cell lines treated with chemotherapeutics
Cell Line 5-Florouracil (uM) Doxorubicin (nM) Carboplatin (uM) Paclitaxel (nM)
ME16C 6.0 (0.29) 32.8 (1.89) 37.5 (0.63) 0.052 (0.004)
HME-CC 1.1 (0.07) 35.5 (3.26) 48.3 (1.41) 0.025 (0.003)
SUM102 16.8 (0.82) 5.1 (0.27) 11.7 (0.26) 0.00057 (0.00001)
SUM149 28.6 (1.33) 45.0 (3.06) 7.7 (0.24) 0.71 (0.006)
MCF-7 1.2 (0.15) 56.9 (4.26) 89.4 (3.79) 0.23 (0.02)
ZR-75-1 8.4 (1.06) 26.5 (1.39) 62.6 (1.98) 0.99 (3.34)
Note that the standard errors are presented within ().
Table 1: Estimated IC50 doses of breast cell lines treated with EGFR, MEK, and PI3K inhibitors 
Cell Line Gefitinib (µM) Cetuximab (µg/mL) U0126 (uM) LY294002 (uM)
ME16C 0.3 (0.02) >100a 19.7 (0.66) 21.2 (0.63)
HME-CC 0.2 (0.01) >100a 12.7 (0.33) 7.3 (0.17)
SUM102 0.1 (0.002) 2.3 (0.15) 4.3 (0.20) 3.4 (0.10)
SUM149 4.7 (0.14) >100a 21.8 (0.80) 18.4 (0.48)
MCF-7 21.1 (0.29) >100a 17.0 (1.15) 3.9 (0.13)
ZR-75-1 11.1 (0.12) >100a 25.0 (0.74) 2.4 (0.05)
72 h IC50 doses were calculated for the EGFR inhibitors gefitinib, cetuximab, the MEK1/2 inhibitor U0126, and the PI3K inhibitor LY294002.
Note that the standard errors are presented within ()
aNo achievable IC50 dose with doses up to 100 µg/mLBMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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Effects of different combination schedules of cetuximab with chemotherapeutics in SUM102 cells Figure 1
Effects of different combination schedules of cetuximab with chemotherapeutics in SUM102 cells. Cells were 
treated with four different combination schedules: 1) 72 h cetuximab followed by 72 h chemotherapy, 2) 72 h chemotherapy 
followed by 72 h cetuximab, 3) 72 h concurrent chemotherapy and cetuximab, and 4) 144 h concurrent chemotherapy and 
cetuximab. A) Growth inhibitory effects of cetuximab and carboplatin combinations. B) Combination analysis of cetuximab 
and carboplatin treatments. C) Growth inhibitory effects of cetuximab and paclitaxel combinations. D) Combination analysis 
of cetuximab and paclitaxel treatments. E) Growth inhibitory effects of cetuximab and 5-fluorouracil combinations. F) Combi-
nation analysis of cetuximab and 5-fluorouracil treatments. G) Growth inhibitory effects of cetuximab and doxorubicin combi-
nations. H) Combination analysis of cetuximab and doxorubicin treatments. Combination Index (CI) values below one are 
synergistic, equal to one are additive, and greater than one are antagonistic.
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than the biological inhibitor first (data not shown). Syn-
ergy was also observed in SUM149 in addition to SUM102
for combinations of gefitinib and carboplatin (see Addi-
tional file 1). U0126 (a MEK inhibitor) combinations
exhibited different results and chemotherapeutics given
first followed by U0126 were slightly less synergistic than
the U0126 first or concurrent treatment; however, for
U0126, all combinations except doxorubicin first, or pacl-
itaxel first, were synergistic (data not shown).
EGFR-associated gene expression patterns in vitro
To identify an EGFR-pathway associated profile, we ana-
lyzed the gene expression data of the SUM102 cell line
treated with EGFR inhibitors (baseline) and then released
from this inhibition to identify those genes that were
induced upon removal of the inhibitor. Using an unsuper-
vised analysis, we hierarchically clustered all time points
from the cetuximab and gefitinib treatment experiments
and identified over 500 genes that changed in expression
at least 4-fold (Figure 2). Even though the two EGFR
inhibitors have different mechanisms of inhibition,
SUM102 cells treated for 48 h with gefitinib or cetuximab
showed very similar gene expression patterns. Intra-class
correlation (ICC) values between the gefitinib and cetuxi-
mab treated samples ranged from 0.627 to 0.934, and this
level of similarity is evident in the short dendrogram
branches from the cluster analysis (Figure 2B). The post
treatment samples (i.e. after removal of inhibitor) that
represent the reactivation of the EGFR-pathway were even
more similar (ICC within each time point ranged from
0.862 to 0.962). A two-class SAM analysis to look for dif-
ferences between gefitinib-post treatment samples versus
cetuximab-post treatment samples identified only 58 sig-
nificantly different genes with a false discovery rate (FDR)
of 5%; thus, from a transcription standpoint, gefitinib and
cetuximab elicited very similar results in SUM102 cells.
In response to gefitinib and cetuximab, the SUM102 cell
line exhibited decreased expression of many proliferation
genes (Figure 2). There was also a large cluster of genes
that were induced by the inhibitors, consisting predomi-
nately of hypothetical genes with unknown functions. We
were more interested in the genes induced after the
removal of the inhibitor as this reflects the gene expres-
sion patterns associated with the reactivation of the EGFR
pathway. As early as 4 h and 8 h after inhibitor removal
there was a substantial increase in expression for two lig-
ands of EGFR, namely amphiregulin and epiregulin. Cyclin
A1 was also substantially increased (Figure 2C and 2D).
Starting at 4 h and continuing through 8 h and 24 h, genes
with known roles in G1/S phase such as CDC6, CDC7,
TIMELESS, and ORCL6 were increased (Figure 2E and see
Additional file 2). By 8 h and 24 h, DNA synthesis and
DNA damage checkpoint genes were induced (Figure 2F).
Classical gene expression-defined proliferation genes
including STK6 and Cyclin B1 were highly induced by 24
h (Figure 2G). There was also a repression of negative reg-
ulators of growth such as Growth arrest-specific 1 and Cyclin
G2 (see Additional file 2).
Role of MEK and PI3K in the in vitro EGFR-profile
Activation of EGFR leads to the downstream activation of
other signaling components including the MEK/ERK and
PIK3/AKT pathways [1]. To examine the role of these
effectors, we treated the SUM102 cell line with the MEK1/
2 inhibitor U0126 and the PI3K inhibitor LY294002
alone, and in combination. Microarray time course exper-
iments using inhibitor treated cells followed by inhibitor
removal were conducted for U0126 and LY294002 similar
what was done for the cetuximab and gefitinib experi-
ments. The observed gene expression profiles for the
U0126 and the LY294002 experiments were similar in
both gene identity and direction when compared to the
cetuximab/gefitinib profile, but gene expression changes
were typically reduced in magnitude. The U0126 and
LY294002 signatures when compared to each other were
very similar at the 4 h and 8 h time points (average ICC =
0.83), but diverged at 24 h post treatment (average ICC =
0.59). The gene expression signatures of LY294002 and
U0126 samples were also correlated with the gefitinib/
cetuximab gene expression patterns at 4 h and 8 h post
treatment (LY294002 compared to gefitinib/cetuximab
ICC = 0.83, U0126 compared to gefitinib/cetuximab ICC
= 0.77). The LY294002 and U0126 24 h post treatment
samples were less correlated with gefitinib/cetuximab 24
h post samples (LY294002 compared to gefitinib/cetuxi-
mab ICC = 0.51, U0126 compared to gefitinib/cetuximab
ICC = 0.41). We also treated cells with LY294002 and
U0126 simultaneously to determine if the combined
treatment would more completely recapitulate the EGFR-
associated profile; the 24 h post combined treatment sam-
ples showed a higher correlation value to the gefitinib/
cetuximab samples (average ICC = 0.73), but still did not
account for the entire gene expression pattern of the 24 h
post cetuximab/gefitinib treatments. These results suggest
that the cetuximab/gefitinib profile could not be simply
attributed to either the MEK or PIK3 pathway, but that the
combination of these two pathways was more representa-
tive of the EGFR-signature than either pathway alone.
EGFR-associated gene expression patterns in vivo
To identify an EGFR-associated in vivo signature, a one-
class SAM analysis was performed using the SUM102 cells
to identify the genes that were statistically induced in the
post treatment samples relative to the inhibitor treated
samples. Adjusting the SAM delta value to obtain the larg-
est gene set with less than 5% FDR resulted in a gene list
that was extremely large (10,017 genes, 4.97% FDR),
therefore, the top 500 induced genes were selected for fur-
ther analysis (0.02% FDR). This gene list was next used toBMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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cluster 248 UNC breast tumor and normal samples repre-
senting all five breast tumor subtypes (Figure 3 and see
Additional file 3). The list of induced genes from the in
vitro  SUM102 experiments were not homogenously
expressed across the tumor samples; therefore, to study
these multiple expression patterns in the tumors, we
defined "clusters" as any gene set that contained a mini-
mum of 20 genes and a Pearson node correlation greater
than 0.55. Using this criteria, we identified three clusters:
Cluster #1 was highly expressed in a mix of breast tumors
that contained all five breast cancer subtypes: luminal A,
luminal B, basal-like, HER2+/ER- and normal-like sam-
ples (Figure 3C, far right dendrogram branch, 35 genes);
Cluster #2 identified a set of tumors that contained 58%
of all basal-like tumors, 48% of all HER2+/ER- tumors
and 3 luminal B tumors (Figure 3D, center dendrogram
branch, 27 genes); Cluster #3 was highly enriched for
luminal A and B tumors, and was also highly expressed in
Gene expression patterns for SUM102 cells treated with gefitinib or cetuximab Figure 2
Gene expression patterns for SUM102 cells treated with gefitinib or cetuximab. Unsupervised hierarchical cluster 
analysis was performed on 48 h inhibitor treated and 4 h, 8 h, and 24 h post 48 hr inhibitor treated samples. A) The complete 
cluster overview with the colored bars indicating the location of the clusters shown in C-G. B) Close up of the experimental 
sample associated dendrogram. C+D) 4 h and 8 h post treatment induced genes including the EGFR ligands Amphiregulin and 
Epiregulin. E) Genes involved with the G1/S phase transition induced beginning in the 4 h post inhibitor and continuing though 
24 h. F) Genes involved in DNA synthesis induced at 8 h post inhibitor and continuing through 24 h. G) Proliferation genes 
typically observed in tumor derived profiles including STK6 and Cyclin B1.
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In vivo EGFR-associated profiles and additional genes implicated in the EGFR-RAS-MEK pathway Figure 3
In vivo EGFR-associated profiles and additional genes implicated in the EGFR-RAS-MEK pathway. A) The top 
500 induced genes from the SUM102 post treatment experiments were hierarchical clustered using the 248 UNC tumors. 
Colored bars indicate the location of the three clusters in D-E. B) Tumor associated dendrogram color coded according to 
tumor subtype: Luminal A – dark blue, Luminal B – light blue, true normals and normal-like – green, HER2+/ER-negative – pink, 
and basal-like – red. C) Cluster #1 that identified a mixed group of tumors. D) Selected genes from the center of Cluster #2 
that are high in most basal-like tumors. E) Selected genes from the center of Cluster #3 that are high in the luminal tumors. F) 
Data for genes with suggested roles in EGFR-pathway. G) Data for the KRAS-amplicon signature identified in Herschkowitz et 
al. [35].
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most of the HER2+/ER- and basal-like tumors that were
also high for Cluster #2 (Figure 3E, left dendrogram
branch- luminal A and B tumors, and center dendrogram
branch – HER2+/ER- and basal tumors, 139 genes). Thus
each gene cluster could represent a distinct EGFR-associ-
ated signature that is enriched in different subsets of
tumors (for full gene lists for each cluster see Additional
File 4). Gene Ontology (GO) analysis using EASE was per-
formed on each gene cluster but only Cluster #3 had any
significant GO terms, which were RNA processing, metab-
olism, binding, splicing, and modification (EASE scores <
0.05). Cyclin E1 was present within Cluster #2 and is a
known prognostic marker for breast cancer patients [27];
Cyclin E1 is also associated with basal-like breast cancers
[28,29], which was recapitulated here. Lastly, Cyclin E1 is
known to be regulated by EGFR-signaling [30], where
both AKT and ERK can inhibit p27kip1, which is a negative
regulator of CDK2/Cyclin E1 complex [31,32].
To further examine the biological importance of these
three EGFR-associated gene sets, we individually applied
them to a test set of breast tumors (i.e. the NKI295 sample
set described in [33,34]) and determine whether they pre-
dicted patient outcomes. First, we determined a mean
expression value of all genes within each cluster for each
patient. Next, the patients were rank-ordered according to
their mean expression values for each cluster and divided
into halves or thirds. Kaplan-Meier survival analyses for
Table 3: Multivariate Cox Proportional Hazards analysis of EGFR clusters with clinical parameters in NKI295 data set 
Relapse Free Survival Overall Survival
Variable Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value
Standard clinical parameters
Age, per decade 0.59 (0.43–0.81) 0.001 0.67 (0.45–0.99) 0.04
ER status 0.64 (0.42–0.98) 0.04 0.45 (0.27–0.71) 0.0009
Size 1.38 (0.94–2.02) 0.10 1.50 (0.94–2.41) 0.09
Tumor grade 2 vs. 1 2.41 (1.31–4.43) 0.005 4.30 (1.48–12.35) 0.007
Tumor grade 3 vs. 1 2.58 (1.38–4.81) 0.003 6.02 (2.09–17.35) 0.0009
Nodes 1–3 vs. 0 0.85 (0.55–1.32) 0.48 0.91 (0.53–1.56) 0.72
Nodes >3 vs. 0 1.37 (0.83–2.26) 0.22 1.56 (0.85–2.85) 0.14
Standard clinical parameters and Cluster #1
Age, per decade 0.59 (0.43–0.82) 0.002 0.67 (0.45–0.99) 0.05
ER status 0.67 (0.43–1.04) 0.08 0.45 (0.27–0.75) 0.002
Size 1.35 (0.92–1.99) 0.12 1.48 (0.92–2.39) 0.11
Tumor grade 2 vs. 1 2.26 (1.23–4.18) 0.009 4.13 (1.42–11.98) 0.009
Tumor grade 3 vs. 1 2.21 (1.16–4.22) 0.02 5.34 (1.81–17.74) 0.002
Nodes 1–3 vs. 0 0.82 (0.56–1.27) 0.38 0.86 (0.50–1.50) 0.60
Nodes >3 vs. 0 1.23 (0.73–2.06) 0.43 1.46 (0.79–2.71) 0.23
Cluster #1 med vs. low 1.53 (0.93–2.53) 0.10 1.25 (0.65–2.39) 0.50
Cluster #1 high vs. low 1.70 (1.01–2.88) 0.05 1.43 (0.76–2.69) 0.27
Standard clinical parameters and Cluster #2
Age, per decade 0.60 (0.43–0.83) 0.002 0.67 (0.452–0.99) 0.04
ER status 0.73 (0.46–1.16) 0.18 0.54 (0.32–0.91) 0.02
Size 1.41 (0.96–2.07) 0.08 1.52 (0.94–2.44) 0.09
Tumor grade 2 vs. 1 1.94 (1.05–3.61) 0.04 3.36 (1.15–9.83) 0.03
Tumor grade 3 vs. 1 1.74 (0.90–3.37) 0.10 3.54 (1.20–10.73) 0.02
Nodes 1–3 vs. 0 0.80 (0.52–1.23) 0.31 0.81 (0.47–1.39) 0.44
Nodes >3 vs. 0 1.19 (0.71–1.98) 0.51 1.36 (0.74–2.49) 0.32
Cluster #2 med vs. low 2.13 (1.22–3.71) 0.008 2.10 (0.95–4.64) 0.07
Cluster #2 high vs. low 2.63 (1.44–4.79) 0.002 3.46 (1.58–7.59) 0.002
Standard clinical parameters and Cluster #3
Age, per decade 0.58 (0.42–0.81) 0.001 0.67 (0.45–0.98) 0.04
ER status 0.68 (0.43–1.07) 0.10 0.45 (0.27–0.76) 0.003
Size 1.39 (0.95–2.03) 0.10 1.49 (0.93–2.41) 0.10
Tumor grade 2 vs. 1 2.30 (1.24–4.24) 0.008 4.13 (1.42–12.00) 0.009
Tumor grade 3 vs. 1 2.29 (1.20–4.38) 0.01 5.38 (1.83–15.80) 0.002
Nodes 1–3 vs. 0 0.83 (0.54–1.29) 0.41 0.86 (0.50–1.49) 0.60
Nodes >3 vs. 0 1.30 (0.79–2.16) 0.31 1.47 (0.80–2.70) 0.22
Cluster #3 med vs. low 1.32 (0.81–2.16) 0.26 1.54 (0.80–2.95) 0.20
Cluster #3 high vs. low 1.41 (0.84–2.37) 0.19 1.43 (0.73–2.78) 0.29
Age was a continuous variable grouped in decade years, size was a binary variable (0 = < 2 cm, 1 = > 2 cm), tumor grade 2 and 3 are relative to grade 1, and node 
status (1–3 nodes or > 3 nodes) was relative to 0 positive nodes. Expression of the three clusters was averaged, rank ordered, divided into equal thirds; medium 
and high expression is relative to low expression. Significant variables are displayed in bold.BMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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Relapse-Free Survival (RFS) and Overall Survival (OS)
were performed and all three clusters were statistically sig-
nificant predictors of outcomes where high expression
always predicted a poor outcome (Figure 4 – OS; data not
shown for RFS). High expression of clusters #2 and #3
were also significant predictors of RFS and OS in the UNC
training data set (data not shown). Using a Cox regression
analysis, we tested each cluster with the standard clinical
parameters and determined that the high expression (top
third) of Cluster #2 compared to the lowest expression
(bottom third) significantly predicted a worse outcome
for both RFS and OS (Table 3) after controlling for age, ER
status, size, grade, and node status. Since the NKI295 data
set was enriched for node-negative tumors less than 5 cm
in diameter, tumor size and node status were not signifi-
cant in the multivariate analysis [33,34]. Chi-squared
analyses were performed to identify relations between
tumor subtypes and Clusters #1–3. Consistent with obser-
vations from Figure 3, the basal-like, luminal B, and
HER2+/ER- tumors were associated with the high expres-
sion of all three clusters while the luminal A and normal-
like samples rarely showed high expression (Table 4, p =<
0.0001); in particular, the majority of basal-like tumors
were almost all high for Cluster #2 (89% in top 1/3).
Analysis of EGFR-pathway components relative to 
expression patterns in vivo
Since most of the genes from the in vivo focused EGFR-
associated signatures were not established members of the
HER-signaling pathway, we examined the gene expression
patterns of many of the known pathway components for
their ability to predict patient outcomes, and determined
if they showed correlations to any of the EGFR-associated
profiles. Gene expression data for three-fourths of the
HER family of receptors (EGFR, HER2, HER4), some of
their ligands (TGFA, EGF, AREG), as well as other pathway
components including MEK1, MEK2, PIK3CA, PIK3R1,
CRYAB, AKT1-3, the RAS proteins (H, K and N), ERK1,
ERK2, and a KRAS-amplicon signature (identified and
defined in Herschkowitz et al. [35]), were individually
tested for the ability to predict patient outcomes, for cor-
relations with tumor subtype (Table 4), and for correla-
tions with the EGFR-associated expression Clusters #1–3
(Table 5). Gene expression for individual genes was rank-
order and divided into thirds as was done for Clusters #1–
3 previously, and each gene was tested for its ability to pre-
dict outcomes in the UNC 248 and NKI 295 tumor data
sets. No individual gene's expression pattern listed above
significantly predicted RFS and OS in both the UNC and
NKI data sets.
Kaplan-Meier survival plots for the 295 NKI tumors/patients using the in vivo defined EGFR-associated profiles Figure 4
Kaplan-Meier survival plots for the 295 NKI tumors/patients using the in vivo defined EGFR-associated profiles. 
The average expression value for each cluster in each patient was determined and the patients then put into rank-order and 
divided into two equal groups or three equal groups. Overall survival analysis was performed for each cluster. X indicates cen-
sored data due loss to follow-up or to information at last checkup. Note that Clusters #2 and #3 were also similarly prognos-
tic for the UNC 248 training data set.
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Associations of genes or clusters with intrinsic subtype
were examined using Chi-square analysis and many sig-
nificant associations were identified (Tables 4). For exam-
ple, high HER2 expression, as expected, was significantly
correlated with the HER2+/ER- subtype and high ER
expression was associated with both luminal subtypes
(data not shown). EGFR expression was correlated with
the basal-like subtype, while high HER4,  AREG, and
PIK3R1 expression was associated with the luminal A sub-
type. Many other associations with the basal-like subtype
were also evident that included the high expression of
Clusters #1–3, TGFA, AKT3, CRYAB, MEK1, NRAS, KRAS
gene and the KRAS-amplicon signature (Table 4). Other
potentially biologically relevant associations included the
high expression of Clusters #2 and #3, HRAS, MEK1, and
AKT1 with the HER2+/ER- subtype, and high expression
of Clusters #1–3 and HRAS with the luminal B subtype.
Even though Clusters #1–3 were identified using a basal-
like tumor derived cell line, associations with luminal and
HER2+/ER- tumors were identified.
We also tested for associations between the high expres-
sion of Clusters #1–3 with the high expression (i.e. top 1/
3 highest group) of each of the above-mentioned genes in
both the UNC and NKI datasets (Table 5). In both data-
sets, the high expression of MEK2 and HRAS was associ-
ated with Cluster #1, while the high expression of many
other genes correlated with Clusters 2 and 3; of note was
the high expression of the KRAS-amplicon, HRAS, NRAS,
and MEK1 with both Clusters #2 and #3, and the high
expression of EGFR with only Cluster #2. The association
of different genes with the three EGFR-associated signa-
tures is likely reflective of the complexity of signaling in
this pathway across breast cancers and suggests possible
driving molecular mechanisms for each EGFR-associated
profile.
Lastly, a previously described mechanism for activation of
the EGFR-RAS-MEK pathway is the somatic mutation of a
RAS gene, BRAF, or EGFR, which can be relatively frequent
events in non-small cell lung carcinomas. We performed
sequencing analyses on a subset of the UNC breast tumors
analyzed by microarray for EGFR mutations in exons 19
Table 4: Chi-square analysis for association of gene expression with subtypes 
Basal-like HER2+/ER- Luminal A Luminal B Normal-like p-value
# tumors 53 35 123 55 29
Cluster 1a 68% 37% 12% 56% 14% <0.0001
Cluster 2a 89% 49% 5% 49% 7% <0.0001
Cluster 3a 77% 51% 11% 47% 0% <0.0001
EGFRa 68% 20% 27% 18% 41% <0.0001
HER2a 15% 100% 28% 26% 24% <0.0001
HER4* 9% 3% 50% 38% 31% <0.0001
TGFAb 74% 37% 17% 25% 38% <0.0001
AREGa 3% 34% 43% 35% 41% <0.0001
EGF 17% 40% 37% 36% 31% 0.23
CRYABa 70% 11% 33% 4% 48% <0.0001
KRAS amplicona 68% 40% 24% 35% 0% <0.0001
KRAS genec 32% 37% 33% 38% 21% 0.36
HRASd 32% 66% 17% 64% 7% <0.0001
NRASa 70% 28% 17% 44% 21% <0.0001
PIK3CA 30% 17% 36% 36% 41% 0.28
PIK3R1a 21% 14% 42% 25% 55% 0.0012
AKT1a 26% 63% 27% 40% 24% <0.0001
AKT2* 26% 40% 27% 47% 38% 0.26
AKT3a 51% 14% 39% 9% 45% <0.0001
MEK1 53% 46% 25% 29% 24% 0.023
MEK2e 42% 43% 25% 42% 24% 0.068
ERK1f 30% 26% 31% 42% 41% 0.49
ERK2g 40% 31% 26% 45% 31% 0.048
Samples were rank ordered into three equal groups and the percentage of each subtype in the highest expression group is reported for the NKI patient data set.
*Note: HER4 could not be assessed in UNC data due to too many missing values; HER3 was not present in the NKI data set; AKT2 was not present in the UNC 
data set
a associations were also similarly significant in the UNC sample set
b nominally significant in UNC data (p-value = 0.0046)
c nominally significant association in the UNC data (p-value= 0.0051)
d nominally significant in the UNC data (p-value = 0.003)
e nominally significant in the UNC data (p-value = 0.0023)
f significant in the UNC data (p-value = 0.0003)
g significant in the UNC data (p-value = <0.0001)
Bonferroni corrected level of significance α = 0.0022BMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
Page 11 of 19
(page number not for citation purposes)
and 20, and for the common mutations in HRAS, KRAS
and BRAF. No somatic sequence variants were detected in
the 96 tumors that were analyzed, which were over sam-
pled for basal-like and HER2+/ER- tumors.
Discussion
The epidermal growth factor receptor family is of tremen-
dous biological and clinical importance for many solid
epithelial tumors. In breast cancer patients, the response
rate to single agent EGFR inhibitors has been low, how-
ever, these trials were performed on unselected patient
populations [36,37] and response rates might be
improved within biologically selected tumor subsets. The
EGFR-pathway has become a potential target in the basal-
like subtype because at least 50% of basal-like tumors
express EGFR as assessed by IHC [6]. Our in vitro analyses
show that all basal-like cell lines tested were more sensi-
tive to gefitinib compared to luminal cell lines. Only a sin-
gle cell line (SUM102) was sensitive to cetuximab when
EGF was present in the media, which is the condition that
best mimics the in vivo environment [38].
Given the importance of combination therapies, we eval-
uated the combination of cetuximab and various chemo-
therapeutics in SUM102 cells and observed that the
combination of cetuximab and carboplatin was highly
synergistic at low doses of each drug. Even though the
short-term co-treatment of cetuximab and carboplatin
was antagonistic, synergism was observed in the long-
term co-treatment. Carboplatin, as well as other platinum
derivatives, may also be good chemotherapeutic agents
for basal-like breast cancers due to the implicated func-
tion of the BRCA1-pathway in this subtype because
BRCA1 mutation carriers are likely to develop tumors of
the basal-like phenotype [3,39,40]. In our basal-like
tumor-derived cell lines, it has been reported that the
SUM149 line has a BRCA1 mutation and SUM102 line
has barely detectable transcript levels of BRCA1  [41].
From a mechanistic standpoint, BRCA1  is required for
repair of cisplatin induced DNA damage by recruiting
RAD51 to the site of damage [42,43] and BRCA1-deficient
cells exhibit increased sensitivity to cisplatin compared to
wild type cells [44-47]. The combination of an EGFR
inhibitor and a platinum drug has also been found to be
synergistic in several other cell types [14,48,49]. In our
experiments, we showed that not only are the basal-like
tumor derived cell lines the most sensitive to carboplatin
and the EGFR inhibitors when applied individually, but
also that the combination was synergistic. These results
provide supportive preclinical evidence for an ongoing
clinical trial for "triple-negative/basal-like" (i.e. ER-nega-
tive, PR-negative, and HER2-nonamplified) metastatic
breast cancer patients who are receiving either cetuximab
alone versus cetuximab plus carboplatin [50].
Given the biological importance of the EGFR pathway in
epithelial tumors, we identified an EGFR-associated pro-
file in vitro and examined its interplay with other biologi-
cal features in vivo. In primary breast tumors, the SUM102-
defined set of EGFR-associated genes was broken into
three distinct expression patterns (Figure 3), of which the
high expression of two predicted poor patient outcomes
in both the training and test data sets (i.e. Clusters #2 and
#3). The prognostic ability of these clusters was further
analyzed in the test set and Cluster #2 could predict poor
outcomes even after controlling for the standard clinical
parameters in a Cox multivariate analysis. Of the three sig-
natures, Cluster #2 was the only cluster significantly asso-
ciated with high EGFR gene expression.
Since most of the EGFR-associated in vivo profile genes did
not have obvious functions in the HER family pathway
(aside from Cyclin E1 in Cluster #2), we searched for cor-
relations with the expression levels of well known genes
in the pathway. Many relationships were identified that
could have important mechanistic implications (Tables 4
and 5). To assist in the interpretation of these complex
patterns, we used the program Cytoscape [51,52] to dis-
play the gene expression data in a pathway styled format
and highlighted the statistically significant associations
observed within each subtype (Figure 5). Each subtype
had a distinct EGFR-pathway cartoon relative to both the
EGFR-associated profiles, as well as the expression of key
genes from the EGFR-RAS-MEK pathway. The luminal A
subtype showed low expression of most of the genes we
examined in the HER family pathway, and on average,
was low for all three EGFR-associated profiles. One of the
few genes whose high expression was significantly corre-
lated with this subtype was the HER4 receptor (Figure 5A);
high expression of HER4 and average expression of two of
its ligands (HB-EGF  and  NRG1) was observed in this
tumor subtype that typically shows low grade, slow
growth, and an ER-rich expression signature.
The luminal B tumors showed moderate to high expres-
sion of the EGFR-associated profiles, high HRAS expres-
sion, and potentially high MEK2 expression (Figure 5B).
The EGFR-HER2 pathway has often been implicated as a
potential mechanism for tamoxifen resistance in ER+
patients [36,53-57]. We determined that the high expres-
sion of the EGFR-associated profiles was able to predict
outcome differences in ER+ and tamoxifen-treated
patients in both the UNC and NKI data sets (data not
shown); however, it should be noted that the expression
of these clusters in ER+ patients closely parallels the dis-
tinction of luminal A versus luminal B. These results sug-
gest that part of the luminal A versus luminal B distinction
is due to the activation of the EGFR/HER2 pathway in
luminal B tumors. In support of this hypothesis, ninety-
six percent of the luminal B tumors showed high expres-BMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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sion of at least one of the three EGFR-associated clusters,
whereas only 24% of luminal A tumors had high expres-
sion of at least one. Our results are also consistent with the
hypothesis of the "non-genomic" effects of ER to activate
the HER pathway, where membrane bound ER complexes
with EGFR and/or HER2 to cause activation of the RAS-
MEK and p38 pathways [53,54,58], and suggests that
these ER "non-genomic" effects are occurring in luminal B
tumors. Response to EGFR inhibitors in ER-positive
tumors have been mixed with some indicating a benefit
[59,60], while others found no benefit [57]. A hypothesis
that could be tested is that the high expression of one or
more of the EGFR-associated gene sets in ER+ tumors
might correlate with response/benefit to EGFR inhibitors.
The HER2+/ER- tumors, as expected, showed statistically
high expression of HER2 and were also associated with
high HRAS and MEK1/MEK2 (Figure 5C). High AKT1 lev-
els were also associated with this tumor subtype, which
has been previously identified [61,62].
The basal-like subtype showed the high expression of each
of the three EGFR-associated profiles; ninety-one percent
of the basal-like tumors had high expression of at least
one of the signatures with 58% of the tumors having high
expression of all three. High expression of many of the
genes in the EGFR-RAS-MEK pathway were also signifi-
cantly correlated with the basal-like subtype including
EGFR, TGFα, MEK1, MEK2, AKT3, CRYAB, NRAS and the
KRAS-amplicon signature (Figure 5D). For many of the
genes or clusters examined here, as many as 70% of the
basal tumors were in the highest 1/3 expression group
when compared to all other tumors. These data, when
coupled to the EGFR inhibitor studies on breast cells lines,
strongly suggest that the EGFR-RAS-MEK pathway plays
an important role in the basal-like subtype's biology, and
may be a requisite activating event for tumor formation.
The pathway analysis of the basal-like subtype has also
potentially provided important mechanistic clues about
how the EGFR-RAS-MEK pathway is activated in basal-like
Table 5: Associations between Clusters #1–3 and individual genes using the NKI295 sample set 
Cluster 1 Cluster 2 Cluster 3
% p-val % p-val % p-val
EGFR 39% 0.1783 43% 0.0091b 38% 0.15
HER2 26% 0.0017 25% <0.0001c 24% <0.0001a
HER4* 21% <0.0001 12% <0.0001 18% <0.0001
TGFA 40% 0.0665 48% 0.0002 47% 0.0021
AREG 22% 0.0007c 23% <0.0001a 28% 0.064f
EGF 35% 0.1380 25% 0.0691 27% 0.033d
CRYAB 35% 0.3214f 38% 0.0524 38% 0.0013
KRAS amplicon 38% 0.1973e 52% <0.0001c 63% <0.0001a
KRAS gene 27% 0.0022a 31% 0.8795 36% 0.14e
HRAS 48% <0.0001c 51% <0.0001 47% 0.0018
NRAS 45% 0.0362 56% <0.0001c 59% <0.0001a
PIK3ca 22% 0.0032b 27% 0.1415e 30% 0.33e
PIK3R1 24% 0.0009a 20% <0.0001a 19% <0.0001
AKT1 41% 0.0112 39% 0.0899 34% 0.36
AKT2* 40% 0.0519 37% 0.3524 33% 0.94
AKT3 26% 0.0004 33% 0.1569 35% 0.64f
MEK1 39% 0.0335 47% 0.0032d 48% <0.0001
MEK2 58% <0.0001a 44% 0.0113d 36% 0.55f
ERK1 37% 0.0718e 23% 0.0009c 19% <0.0001a
ERK2 39% 0.0238 37% 0.3457e 36% 0.46e
Chi-squared analyses were used to identify associations between the high expression of the individual EGFR-activation profiles for each cluster (top 
1/3) and the expression of individual genes categorized as high (top 1/3). The % of tumors with the high expression of each cluster and that show 
the high expression of the individual gene is shown.
*Note: HER4 could not be assessed in UNC data due to too many missing values; HER3 was not present in the NKI data set; AKT2 was not 
present in the UNC dataset.
a the statistically significant association was also significant in the UNC data set (p < 0.0025).
b the association was nominally significant in the NKI dataset (p < 0.05), but significant in the UNC dataset (p < 0.0025).
c the association was significant in the NKI dataset (p < 0.0025), but nominally significant in the UNC dataset (p < 0.05).
d the association was nominally significant in both datasets (p < 0.05).
e the association was significant in UNC dataset (p < 0.0025).
f the association was nominally significant in the UNC dataset (p < 0.05).
Bonferroni corrected level of significance α = 0.0025BMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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EGFR pathway diagram displayed for each breast tumor subtype Figure 5
EGFR pathway diagram displayed for each breast tumor subtype. The average gene expression value for each gene 
within each subtype is displayed for the EGFR-pathway and for the three EGFR-activation profiles using the UNC 248 tumor 
dataset. Eight genes from the middle of each of the three EGFR-activation clusters were used to view expression of the clus-
ters in each of the subtypes. A pink node border identifies the genes that showed statistically significant associations with sub-
type. *Note: the NKI HER4 data spot was used since HER4 was not present in the UNC data set. A) Luminal A, B) Luminal B, 
C) HER2+/ER- and D) Basal-like.
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tumors. One example concerns CRYAB, which has previ-
ously been shown to be highly expressed in many basal-
like tumors and to portend a poor outcome. Moyano et al.
showed that the ectopic expression of CRYAB in breast
epithelial cells caused them to become transformed and
EGF-independent through activation of MEK [21]. This
transformed phenotype was reverted by the addition of
the MEK inhibitors PD98059 and U0126, while the PIK3
inhibitor LY294002 had little effect. CRYAB could also
potentially confer resistance to EGFR inhibitors as well as
chemotherapy by its anti-apoptotic mechanism, which is
via the inhibition of caspase-3 activation [63,64]. Other
potential activation events include the high expression of
HRAS and KRAS; in particular, the KRAS-amplicon signa-
ture (which has also been identified in a murine model of
basal-like tumors[35,65]), was highly expressed in 70% of
the basal-like tumors and was shown to correlate with
high expression of Cluster #2. Given that most basal-like
tumors showed either high expression of CRYAB or the
KRAS-amplicon signature (greater than 85%), drug target-
ing of the EGFR-RAS-MEK pathway downstream of EGFR
(i.e. MEK inhibitors) might offer a more effective therapy
than targeting of EGFR directly.
While these experiments only address gene expression
patterns and not the protein levels or phosphorylation
status of EGFR or RAS or MEK, we believe it is likely that
these signatures are bona fide EGFR-pathway activation
signatures. The supportive data for this hypothesis
includes the in vitro observations that these are genes
induced when an EGFR-dependent cell line is freed from
growth inhibition via EGFR inhibitors and the in vivo
associations between the high expression of these signa-
tures and genes including HRAS, KRAS and EGFR itself.
Regardless of the classical markers of activation of the
EGFR-RAS-MEK pathway, the strong associations between
these expression profiles and patient outcomes in two dif-
ferent data sets suggest that they are important profiles.
Currently, we have chosen only to validate our profiles
using additional microarray data sets, as opposed to using
western blots or quantitative PCR of the training set, since
each of these signatures represents a large number of
genes/proteins. Many of these genes have no current link
to the EGFR-signaling pathway and we cannot be sure of
which genes are driving the prognostic significance of the
clusters. If these signatures show additional promise for
clinical application, detailed follow up will dissect which
genes are important for prognosis, and then they will be
confirmed using other platforms. Perhaps another utility
of these profiles might be the ability to predict response to
EGFR inhibitors, however, we could not test this hypoth-
esis, as there are currently no large epithelial tumor EGFR
inhibitor treated microarray data sets available. However,
we believe that these signatures could represent a dynamic
descriptor of pathway activity compared to EGFR protein
status alone, which does not predict responsiveness to
EGFR inhibitors [66-68].
Conclusion
The EGFR pathway is a complex signaling network and
differences in gene expression levels of its various compo-
nents can be observed across the breast cancer subtypes.
EGFR-associated gene expression profiles derived in vitro
were prognostic in two independent breast tumor data
sets. Using these EGFR-associated gene expression pro-
files, and gene expression levels of known genes within
the EGFR pathway, we have identified key differences in
this pathway across the subtypes. A better understanding
of each subtype's EGFR signaling pathway will have an
impact on identifying and determining treatment as the
gene expression signature may more readily be associated
with activation of the pathway than EGFR status alone.
Methods
Cell culture
SUM102 and SUM149 cells were a gift from Steve Ethier
of Wayne State University [69] and represent cell lines
derived from ER- and HER2- basal-like breast tumors. The
SUM cell lines were maintained in an Epithelial Growth
Medium developed by the Tissue Culture Facility at the
University of North Carolina at Chapel Hill [70], and the
SUM149 line was further supplemented with 5% FBS. The
MCF-7, ZR-75-1, HME-CC and ME16C cell lines were
obtained and maintained as previously described [22,23].
Cytotoxicity assay
Cell line sensitivities to drugs were assessed using a mito-
chondrial dye conversion assay (MTT, Cell Titer 96,
Promega, Madison, WI) as described previously with the
following modifications [22]. Cells were seeded into trip-
licate 96-well plates (SUM102, HME-CC, and ME16C –
5,000 cells/well, SUM149 – 10,000 cells/well, MCF-7 and
ZR-75-1 – 7,000 cells/well) and allowed to adhere over-
night. Cells were treated for 72 h with a range of doses of
individual drugs. Carboplatin, doxorubicin, 5-fluorour-
acil, paclitaxel, and LY294002 were purchased from
Sigma (St. Louis, MO). Gefitinib was a gift from Astra-
Zeneca and cetuximab was purchased from the UNC Hos-
pitals Pharmacy Storeroom (Chapel Hill, NC). U0126 was
purchased from Cell Signaling (Danvers, MA). The inhib-
itory concentration that caused a 50% reduction in MTT
dye conversion (IC50) dose was determined as previously
described [22].
Drug combination interactions were analyzed using
methods developed by Chou and Talalay [26]. Using cell
lines plated as described above, seven treatment combina-
tions consisting of constant ratios of IC50 doses (ranging
from one-eighth of each dose to eight times the IC50)
were applied to cells and growth compared to untreatedBMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
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controls using the MTT assay. Four treatment schedules
were tested: 72 h concurrent, 72 h inhibitor followed by
72 h chemotherapeutic, 72 h chemotherapeutic followed
by 72 h inhibitor, and a 144 h concurrent dose with a
media change at 72 h (similar to the sequential treat-
ments). CalcuSyn (BioSoft, Cambridge, UK) was used to
determine the combination index, which is a measure-
ment of the type of drug interactions. A combination
index (CI) of one indicates an additive response, less than
one indicates a synergistic response (greater than addi-
tive), and greater than one indicates an antagonistic
response (less than additive).
Collection of mRNA for cell line experiments
For each treatment, the SUM102 cells were grown in 15-
cm dishes until 50–60% confluence. SUM102 cells were
treated for 48 h with a dose equivalent to two times the
72h-IC50 dose of each inhibitor (treated samples). To
identify EGFR, MEK, and PI3K activation signatures, the
medium was removed after 48 h of inhibitor treatment
and replaced with fresh medium without inhibitor.
mRNA was harvested at 4 h, 8 h, and 24 h (post treatment
samples). Cells were harvested by scraping, quickly placed
into RNA lysis buffer, and mRNA was isolated using the
Micro-FastTrack kit (Invitrogen, Carlsbad, CA).
Collection of RNA for human tumor samples
248 breast tissue samples represented by 241 fresh frozen
breast tumor samples and 7 normal breast tissue samples
were obtained from four different sources using IRB
approved protocols from each participating institution:
the University of North Carolina at Chapel Hill, The Uni-
versity of Utah, Thomas Jefferson University and the Uni-
versity of Chicago; many of these samples have appeared
in previous publications [71-74], and 117 are new to this
study (see Additional file 5). The patients were heteroge-
neously treated in accordance with the standard of care
dictated by their disease stage, ER, and HER2 status.
Tumor sequence analysis
Tumor genomic DNA samples were isolated from 96
tumors using Qiagen (Valencia, CA) DNeasy Kits accord-
ing to the manufacturers protocol. Gene sequencing anal-
yses were performed at Polymorphic DNA Technologies
(Alameda, CA) using an ABI 3730xl DNA sequencer and
cycle sequencing, according to the manufacturers proto-
col. A two-step "boost/nested" PCR strategy was used
where first a PCR reaction is performed to generate a larger
DNA fragment, which is then used as a template for the
nested reaction with a second set of PCR primers. Double
stranded sequencing was performed on the nested prod-
uct using the nested PCR primers as the sequencing prim-
ers. Exons 19 and 21 of EGFR were sequenced across all 96
patients, while exons 1 and 2 of KRAS2, 1 and 2 of HRAS,
and 11 and 15 of BRAF were sequenced across 54 patients.
No somatic alterations were detected.
Microarray experiments
For the human tumor samples, the total RNA isolation
and microarray protocols were performed as described in
Hu et al. [5]; in this study, a number of tumor samples
from previous studies were retested using a new custom
Agilent microarray enriched for breast cancer genes. For
cell lines experiments, labeled cRNA was generated from
the mRNA using Agilent's Low RNA Input Linear Amplifi-
cation Kit as described in Hu et al. [5]. For the cell line
studies, the 48 h inhibitor treated samples were compared
to an untreated cell line reference to look for effects of an
inhibitor, and for the post treatment samples, to identify
an activation signature for that drug/pathway. Labeled
experimental sample (Cy5 CTP) and reference (Cy3 CTP)
were mixed and co-hybridized overnight on the same
Custom 22K Agilent Human Whole Genome Oligonucle-
otide Microarray described above. Two to four microar-
rays per experimental cell line condition were performed,
including a dye-flip replicate for gefitinib- and cetuximab-
treated samples. Microarrays were scanned on an Axon
GenePix 4000B microarray scanner and analyzed using
GenePix Pro 5.1 software. Microarray raw data were
uploaded into the UNC Microarray Database and Lowess
normalization was performed on the Cy3 and Cy5 chan-
nels. The microarray and patient clinical data are available
at UNC Microarray Database [75] and have been depos-
ited in the Gene Expression Omnibus under the accession
number GSE6128.
Statistical analyses
Intra-class correlations between cell line microarray exper-
iments were performed to judge the degree of concord-
ance between experiments/samples as described in Hu et
al. [5]. Unsupervised analyses of the cell line samples were
performed by selecting genes with an absolute signal
intensity of at least 30 units (our cutoff for background
signal intensity) in both channels in at least 70% of the
samples tested and that also showed a Log2 R/G Lowess
normalized ratio of two on at least two arrays. The pro-
gram Cluster was used to hierarchically cluster samples
and genes, and Treeview was used to view the data
[76,77]. Using the SUM102 treated cells, a one-class Sig-
nificance Analysis of Microarrays (SAM) was used to iden-
tify significantly induced genes in all the post treatment
experiments (two to three arrays for each experimental
time point) [78]. Gene ontology enrichment was assessed
using EASE [79].
Analyses of the primary tumor data used the top 500
induced genes from the cell line SAM analysis described
above, after filtering for 30 units in both channels in at
least 70% of the tumor samples. These genes were exam-BMC Genomics 2007, 8:258 http://www.biomedcentral.com/1471-2164/8/258
Page 16 of 19
(page number not for citation purposes)
ined in a two-way hierarchical clustering analysis with the
248 UNC tumor sample set. Three distinct expression pat-
terns were observed and labeled as Clusters #1–3. Next,
the genes in each of these three tumor-defined clusters
were identified in the NKI295 patient data set [33,34],
and a mean expression value for each cluster for each
patient was determined. The NKI295 patients were then
rank-ordered and separated into (a) two equal groups rep-
resenting low and high, or (b) three equal groups repre-
senting low, medium, and high average expression for
each cluster. In addition, similar gene-based rank order
patient stratifications were performed for individual genes
that included EGFR,  HER2,  HER4,  EGF,  TGFA,  AREG,
CRYAB, KRAS, KRAS-amplicon profile, HRAS, NRAS,
PIK3CA, PIK3R1, AKT1, AKT2, AKT3, MEK1,  MEK2,
ERK1, and ERK2. Survival analyses were performed using
Cox-Mantel log-rank test in Winstat for Excel (R. Fitch
Software). Multivariate Cox proportional hazards analysis
was performed in SAS v9.0 (SAS Statistical Software, Cary,
NC) to estimate the hazard ratio associated with cluster
expression in the three groups after controlling for stand-
ard clinical predictors (age, ER status, size, grade, and
node status). Chi Square tests (SAS v9.0) were used to
examine correlations between cluster groups, individual
genes, and tumor subtype.
Gene expression relative levels were visualized in relation
to the EGFR signaling pathway using Cytoscape [51,52].
The pathway was built de novo based on information from
KEGG [80,81], BioCarta [82], and a review by Yarden and
Silowkoski [1] with a focus on the RAS-MEK and PI3K/
AKT components. Using the 248 UNC breast tumor
microarray dataset, an average gene expression profile is
displayed for the Luminal A, Luminal B, basal-like, and
HER2+/ER- tumors. Tumor "intrinsic" subtype was deter-
mined for each sample using the 306 gene Centroid Pre-
dictor described in Hu et al. [71]; the subtype
classifications used for the NKI295 sample set were also
derived from this same centroid predictor and are
described in Fan et al. [83].
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